Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria + tetanus + acellular pertussis + inactivated polio + haemophilus influenzae type b conjugate vaccine
- Development stage
- Unknown
- Lead developer
- CanSino Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This pentavalent combination vaccine, developed by CanSino Biologics, is designed to protect infants and children against five major infectious diseases: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, and invasive diseases caused by Haemophilus influenzae type b (Hib). A key feature of this vaccine is its use of CanSino's proprietary 'component' acellular pertussis (DTcP) technology. Unlike traditional DTaP vaccines that use co-purified pertussis antigens, this genetically engineered vaccine contains three purified pertussis antigens (pertussis toxoid, filamentous hemagglutinin, and pertactin) that are produced and purified individually before being combined in defined ratios. This approach is intended to ensure batch-to-batch consistency and potentially improve safety and immunogenicity. The vaccine also incorporates inactivated poliovirus (IPV) and a Hib capsular polysaccharide conjugated to a carrier protein. While the trivalent DTcP component is in late-stage development (Phase III/Priority Review in China), the full pentavalent combination is currently in early-stage clinical trials.
- Other names
- CanSino pentavalent vaccineDTcP-IPV-Hib vaccineAdsorbed Diphtheria, Tetanus and Acellular Pertussis (Three Components), Inactivated Poliovirus and Haemophilus Influenzae Type b Conjugate Combined Vaccine
02
Targets
PRNP (Cellular Prion Protein)Diphtheria toxin
Beyond the preview
Go deeper on diphtheria + tetanus + acellular pertussis + inactivated polio + haemophilus influenzae type b conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria + tetanus + acellular pertussis + inactivated polio + haemophilus influenzae type b conjugate vaccine.